Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib PK in Relapsed/Refractory MM with Renal Impairment
NCT00721734Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2008
- Primary completion
- Nov 2012
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Started Nov 2008; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00721734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00721734.